Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephalon ‘committed to developing orphan disease treatments’

Cephalon ‘committed to developing orphan disease treatments’

4th September 2007

Cephalon has reported that it is dedicated to the development of treatments for orphan diseases – rare conditions affecting a limited number of individuals.

The company reports that its investigational chronic lymphocytic leukaemia (CLL) treatment Treanda (bendamustine HCl) has been granted orphan drug status by the Office of Orphan Products at the US Food and Drug Administration (FDA).

Approximately 15,000 new cases of CLL are diagnosed every year in the US, according to figures from the National Cancer Institute in that country.

Cephalon anticipates the submission of a new drug application to the regulatory authorities as a treatment for CLL, while the compound is currently undergoing studies as a therapy for indolent non-Hodgkin’s lymphoma patients who are refractory to rituximab, a monoclonal antibody.

“Cephalon is committed to advancing medications for orphan diseases,” the firm states.

“The company’s first product, Provigil (modafinil) tablets [C-IV], was launched with an orphan drug designation for narcolepsy in 1999.”

Cephalon adds that other products in its portfolio granted orphan drug status include Trisenox (arsenic trioxide), while it has another – CEP-701 (lestaurtinib), currently undergoing clinical development.

In May 2007, Cephalon reported a “dramatic” increase in earnings for the first quarter of the 2007 fiscal year, with this rise in part attributed to its growth of Provigil.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.